LTZ Doses First Participant in Phase 1/1b Trial of LTZ-232
The first-in-human trial evaluates LTZ’s second asset, a bispecific myeloid engager, in mCRC and other solid tumors.
Related stories
Alnylam Reports Quarterly Results Through September 30
Alnylam Pharmaceuticals reported results for the quarter ended September 30. The alert provides no financial figures.
M impact | EQUITY | Oct 29, 2026, 07:15 PM UTC
Riverview Bancorp Reports $2.0 Million Second-Quarter Profit
Riverview Bancorp reported net income of $2.0 million, or $0.10 per diluted share, for the fiscal second quarter ended September 30, 2026. Net interest income was $11.8 million and
M impact | EQUITY | Oct 29, 2026, 07:13 PM UTC
Ligand Pharmaceuticals Reports Quarterly Results Through September 30
M impact | EQUITY | Oct 29, 2026, 07:13 PM UTC
Allegro Microsystems Reports Quarterly Results Through September 30
M impact | EQUITY | Oct 29, 2026, 07:12 PM UTC
Group 1 Automotive Reports Third-Quarter Revenue of $5.4B
Third-quarter revenue fell 6.7% year over year to $5.4 billion. Net income rose to $102.9 million from $13 million; diluted EPS was $8.59.
M impact | EQUITY | Oct 29, 2026, 07:11 PM UTC
Visa Publishes Q4 and Full-Year 2026 Earnings Call Transcript
M impact | EQUITY | Oct 29, 2026, 07:11 PM UTC